Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

Zenith Serialisation Whitepaper

Overcoming the practical challenges of Pharmaceutical Serialization

Is Pharmaceutical Serialization on your radar? With new regulations either being implemented or pending should it be? Serialization entails adding a unique identifier to single saleable units of prescription and some other medicines so they can be tracked and authenticated throughout the supply chain. Requirements for serialization are already active in some parts of the world and they will be …

Ajay Gautam, Executive Director & Head, AsiaPac & Emerging Markets BD at AstraZeneca.png

Book release – Drugs, Politics & Innovation: An Emerging Markets Cocktail

Our former BioPharma Mexico speaker Ajay Gautam, Executive Director & Head, AsiaPac & Emerging Markets BD at AstraZeneca has just announced the release of his new book. The book is available in Kindle, Paperback and Hardcover on Amazon > “In this book, I have discussed my journey through several emerging markets in the context of healthcare innovation using case studies of start-up …

Pharma M&A AstraZeenec and Pfizer Chess Game

Pharma M&A Chess: Who moves next – AstraZeneca or Pfizer?

Pfizer’s intentions on AstraZeneca involve the playing of a high stakes strategic chess game, with each side plotting carefully their next move. Pfizer has until May 26th to make a firm bid on AstraZeneca or walk away and with the episode in the public eye, it will be interesting to see what moves each company makes in the next few …

Download: Re-assessing Orphan Drugs After 4 Years of CED

  2013’s Pharma Pricing & Market Access Europe included discussions and presentations on topics like the valuing of new medicines and the future of value based pricing, achieving market access for orphan & rare disease products, achieving market for diabetes oncology and primary care products, patient access and flexible pricing schemes. An important presentation, notable for its discussion about the …